TALOS

Targeting LRP5 to Increase Bone Formation in Osteoporosis

Coordinatore	ACADEMISCH ZIEKENHUIS LEIDEN    more  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Mr. Nome: Daan Cognome: Katchaki Email: send email Telefono: +31 71 5261389 Fax: +31 71 5248117
Nazionalità Coordinatore	Netherlands [NL]
Sito del progetto	http://www.talosproject.nl/
Totale costo	3˙898˙406 €
EC contributo	2˙904˙304 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-05-01   -   2011-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Mr. Nome: Daan Cognome: Katchaki Email: send email Telefono: +31 71 5261389 Fax: +31 71 5248117	NL (LEIDEN)	coordinator	0.00
2	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Nome: Dina Cognome: Ramamonjisoa Email: send email Telefono: -55260421 Fax: +33-1-55260436(87)	FR (PARIS)	participant	0.00
3	JULIUS-MAXIMILIANS UNIVERSITAET WUERZBURG  Organization address address: SANDERRING 2 city: WUERZBURG postcode: 97070 contact info Nome: Christian Cognome: Gloggengieser Email: send email Telefono: 49931312294 Fax: +49 931 317180	DE (WUERZBURG)	participant	0.00
4	MORPHOSYS AG  Organization address address: LENA CHRIST STASSE 48 city: MARTINSREID PLANEGG postcode: 82152 contact info Nome: Klaus Cognome: De Wall Email: send email Telefono: -89927371 Fax: -899275371	DE (MARTINSREID PLANEGG)	participant	0.00
5	PEPSCAN THERAPEUTICS BV  Organization address address: ZUIDERSLUISWEG 2 city: LELYSTAD postcode: 8243 RC contact info Nome: Ward Cognome: Langendijk Email: send email Telefono: -237489 Fax: -238409	NL (LELYSTAD)	participant	0.00
6	PERCUROS BV  Organization address address: PLESMANLAAN 1 city: LEIDEN postcode: 2333 BZ contact info Titolo: Mr. Nome: Richard Cognome: Plasek Email: send email Telefono: +31 71 711 8090 Fax: +31 71 711 8090	NL (LEIDEN)	participant	0.00
7	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Ms. Nome: Dawn Cognome: Barker Email: send email Telefono: +44-1223 333543 Fax: +44-1223 332988	UK (CAMBRIDGE)	participant	0.00
8	UNIVERSITE DE GENEVE  Organization address address: Rue du General Dufour 24 city: GENEVE postcode: 1211 contact info Titolo: Mr. Nome: Yvan Cognome: Seguin Email: send email Telefono: +41 22 3795020 Fax: +41 22 3795027	CH (GENEVE)	participant	0.00
9	UNIVERSITEIT ANTWERPEN  Organization address address: PRINSSTRAAT 13 city: ANTWERPEN postcode: 2000 contact info Titolo: Ms. Nome: Anne Cognome: Adams Email: send email Telefono: -32652996 Fax: -32652979	BE (ANTWERPEN)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The balance between bone resorption and bone formation determines the mass and structural integrity of the skeleton and is disturbed in osteoporosis. In contrast to the molecular mechanisms regulating bone resorption, knowledge of the mechanisms regulating bone formation is limited. A recent breakthrough has been the identification of a link between bone mass in humans with rare bone disorders and gain- or loss-of function mutations of the Wnt co-receptor LRP5 or the Wnt antagonist sclerostin. The mechanism, however, underlying these actions on Wnt signalling is unclear. We propose studies with the following specific aims: i) to characterize the clinical, bioschemical, radiological and histological features of patients with sclerosteosis, van Buchem disease and other craniotubular hyperostoses ii) to determine the genetic defect in patients with craniotubular hyperostoses and establish putative genotype-phenotype correlations iii) to unravel the molecular mechanism of the inhibitory action of sclerostin on bone formation and to determine how genetic variations in SOST, LRP5 and Wnt signalling pathway modify bone architecture and remodelling iv) to reveal the pattern of sclerostin expression by analysis of the SOST promoter and by histomorphometry of human bone biopsies v) to identify and characterize co-factors of the LRP5 signalling and their in vivo actions in relevant animal models vi) to identify epitopes in sclerostin that mediate the interaction with LRP5, raise peptide-bound protein mimics and test them in vitro and in animal models of bone loss. These studies will not only help understanding the molecular basis of critical signalling pathway in bone formation but will also provide insight into normal and disturbed modulation of bone remodelling. Moreover, they will help in the design of bone forming interventions for the treatment of patients with osteoporosis.'